HER2 overexpression/amplification was found in many human malignant tumors, accounting for about 20% of breast and gastric cancer, 16% of epithelial ovarian cancer, and 1.3% of colorectal cancer [6,7,8,9,10]. This evidence concerns the gene ERBB2 and cancer.